<DOC>
	<DOCNO>NCT02786537</DOCNO>
	<brief_summary>Phase 1 study compare effectiveness 3 approve HCV treatment regimens learn whether work equally well real-world condition . Phase 2 study begin early 2017 compare effectiveness 2 FDA approve HCV treatment . Patients receive HCV therapy community academic clinic offer opportunity consent randomly assign one three regimen observe outcome . Once randomize , medical care , laboratory testing , disease side effect management assume usual care condition , patient-reported outcome collect outside clinic keep pragmatic design principle .</brief_summary>
	<brief_title>Study Oral Treatments Hepatitis C</brief_title>
	<detailed_description>In Phase 1 study , consent subject randomize 1 follow 3 HCV treatment : 1 ) Harvoni® 2 ) Viekira Pak™ 3 ) Zepatier™ ( The addition Ribavirin length treatment determine provider ) . In Phase 2 study , consent subject randomize 1 2 FDA approve HCV treatment : 1 ) 1 ) Harvoni® 3 ) Zepatier™ . Both Phase 1 Phase 2 subject 1 tablespoon blood drawn HCV resistance test future biorepository testing ( subject provide additional consent ) . The result test determine whether genotype 1a subject provide 12 16 wks Zepatier ( randomize Zepatier ) . Following randomization , subject complete patient report outcome questionnaire via electronic device telephone . Following randomization , subject ask complete survey Wk 4 treatment , End Treatment , 1 3 year post treatment . Subjects standard medical care continue . Test result medical record throughout treatment 3 year post treatment collect .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>HCV Genotype 1a 1b Adult patient ( age 18 year old ) Patients prescribed HCV treatment begin treatment three HCV treatment study ( Harvoni , Viekira Pak ( Phase 1 ) , Zepatier ) Inability provide write informed consent HARVONI® cover drug benefit formulary Current historical evidence hepatic decompensation ( variceal bleeding , hepatic encephalopathy , ascites ) Child Pugh ( CTP ) B C Cirrhosis ( document CTP calculation require ) Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hepatitis C</keyword>
</DOC>